New eye drop could ease severe Allergy-Related eye damage
NCT ID NCT06903884
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 23 times
Summary
This study tests whether adding 3% diquafosol eye drops to standard treatment helps people with moderate-to-severe vernal keratoconjunctivitis (VKC), a serious eye allergy. About 94 participants aged 6 and older will receive either diquafosol plus cyclosporine or cyclosporine alone. Researchers will check eye surface healing, symptoms, and quality of life over 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VERNAL KERATOCONJUNCTIVITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.